Latest News

Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model

July 23, 2021

Research published in Nature Scientific Reports on July 2021, presented new findings on dose escalation PET/MRI imaging for biodistribution and trafficking of a Lym-1 CAR T-cell. The study indicates that dosing may be an important consideration for optimizing the transit time of systemically administered CAR T-cells to tumor.

Read More

A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models

July 15, 2020

Peer-reviewed research published on July 15, 2020 in Clinical Cancer Research (A journal of the American Association for Cancer Research) describes the discovery of a new CAR-T signaling construct “DAP 10/12” that circumvents the adverse effects of tonic signaling and provides superior in vivo anti-tumor efficacy with a humanized huLym-1-DAP-CAR T-cells for the treatment of HLA-DR positive human lymphomas.

Read More

News | Joshua Ofman, M.D., MSHS, joins Board of Directors

July 9, 2019

LOS ANGELES–(BUSINESS WIRE)–Cell BT, Inc. (CBI), an immuno-therapy company focused on the discovery and development of innovative cancer therapeutics based on next generation CAR-T antibody constructs directed to novel biological targets, today announced that Joshua J. Ofman, M.D., MSHS, has been appointed to the CBI Board of Directors.

Read Press Release

Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma

December 20, 2017

Peer-reviewed research published on December 20, 2017 in International Journal of Molecular Science from the University of Southern California, Keck School of Medicine reports the design and preclinical evaluation of a second generation Lym-1 CAR using human primary T cells. The study shows that Lym-1 CAR T-cells display epitope-driven cytokine release, proliferation, and cytotoxicity against Lym-1 epitope-positive cell lines, which resulted in a strong and lasting anti-tumor response.

Read More